UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 238

Sortiert nach

Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales

Atherosclerosis, 2015-05, Vol.240 (1), p.190-196

2015

Volltextzugriff (PDF)

Searching for the elusive familial hypercholesterolaemia gene mutations for index patients – using historical laboratory LDL-c results in primary care. A North Wales experience

Atherosclerosis, 2016-09, Vol.252, p.e48-e49

2016

Volltextzugriff (PDF)

Evolocumab & Inclisiran dual therapy for further LDL lowering in a very high cardiovascular risk Familial Hypercholesterolaemia patient with heterozygous gain of function PCSK9 mutation

Atherosclerosis plus, 2023-12, Vol.54, p.S4-S5

2023

Volltextzugriff (PDF)

Familial hypercholesterolaemia - geomapping of the baseline LDL levels and characterisation of LDL receptor mutations for patients diagnosed in the North Wales screening programme 2010–2015

Atherosclerosis, 2016-09, Vol.252, p.e31-e31

2016

Volltextzugriff (PDF)

Development of an e-learning program on Familial Hypercholesterolaemia (FH) for primary care

Atherosclerosis, 2016-02, Vol.245, p.e245-e246

2016

Volltextzugriff (PDF)

Relationship between measurements of non-HDL-cholesterol and LDL-cholesterol in Familial Hypercholesterolaemia

Atherosclerosis, 2016-02, Vol.245, p.e247-e247

2016

Volltextzugriff (PDF)

Optimising detection and management of Familial Hypercholesterolaemia (FH) – Revision of the FH Audit tool to monitor lipid levels

Atherosclerosis, 2016-02, Vol.245, p.e249-e249

2016

Volltextzugriff (PDF)

Web based tools to assess eligibility for genetic testing for Familial Hypercholesterolaemia (FH)

Atherosclerosis, 2016-02, Vol.245, p.e245-e245

2016

Volltextzugriff (PDF)

Dual therapy with inclisiran and evolocumab in a heterozygous FH patient while on maximum statin and ezetimibe dose to achieve LDL targets

Atherosclerosis, 2023-08, Vol.379, p.S115

2023

Volltextzugriff (PDF)

Five year experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in wales: Should the criteria be refined to include age?

Atherosclerosis, 2016-12, Vol.255, p.7-8

2016

Volltextzugriff (PDF)

GENETIC VARIANTS OF UNCERTAIN SIGNIFICANCE (VUS) IN FAMILIAL HYPERCHOLESTEROLAEMIA (FH) IN WALES: YEAR 2 UPDATE

Atherosclerosis, 2016-02, Vol.245, p.e246-e246

2016

Volltextzugriff (PDF)

Implementation of a multidisciplinary approach to diagnosis and management of familial hypercholesterolaemia (FH) in Wales: The role of the FH specialist nurse

Atherosclerosis, 2013-12, Vol.231 (2), p.e7-e7

2013

Volltextzugriff (PDF)

Genetic variants of uncertain significance (VUS) in familial hypercholesterolaemia (FH): Can family based association studies help determine pathogenicity?

Atherosclerosis, 2014-10, Vol.236 (2), p.e304-e304

2014

Volltextzugriff (PDF)

Prevalence of high lipoprotein (A) amongst high cardiovascular risk population in North Wales, United Kingdom

Atherosclerosis, 2022-08, Vol.355, p.54

2022

Volltextzugriff (PDF)

Familial hypercholesterolaemia (FH) in Wales is genetically heterogeneous

Atherosclerosis, 2013-12, Vol.231 (2), p.e2-e2

2013

Volltextzugriff (PDF)

Implementation of familial hypercholesterolaemia(FH) nurse led assessment clinics in South Wales

Atherosclerosis, 2013-12, Vol.231 (2), p.e7-e7

2013

Volltextzugriff (PDF)

(9) Evaluation of genotype scoring criteria for familial hypercholesterolaemia (FH) in wales

Atherosclerosis, 2012-08, Vol.223 (2), p.530-530

2012

Volltextzugriff (PDF)

Methyl isobutyl ketone (MIBK) induction of α2u-globulin nephropathy in male, but not female rats

Toxicology (Amsterdam), 2009-04, Vol.258 (2), p.131-138

2009

Volltextzugriff (PDF)

Methyl isobutyl ketone (MIBK) induction of alpha 2u-globulin nephropathy in male, but not female rats

Toxicology (Amsterdam), 2009-04, Vol.258 (2-3), p.131-138

2009

Volltextzugriff (PDF)

Neurodevelopmental outcome of infants with hypoplastic left heart syndrome

The Journal of pediatrics, 1995-03, Vol.126 (3), p.496-498

1995

Volltextzugriff (PDF)

Dosimetry considerations in the enhanced sensitivity of male Wistar rats to chronic ethylene glycol-induced nephrotoxicity

Toxicology and applied pharmacology, 2008-04, Vol.228 (2), p.165-178

2008

Volltextzugriff (PDF)

Homozygous deletion in KVLQT1 associated with jervell and Lange-Nielsen syndrome

Circulation (New York, N.Y.), 1999-03, Vol.99 (10), p.1344-1347

1999

Volltextzugriff (PDF)

Mouse specific lung tumors from CYP2F2-mediated cytotoxic metabolism: An endpoint/toxic response where data from multiple chemicals converge to support a mode of action

Regulatory toxicology and pharmacology, 2009-11, Vol.55 (2), p.205-218

2009

Volltextzugriff (PDF)

Cardiac microdialysis in isolated rat hearts: interstitial purine metabolites during ischemia

American journal of physiology. Heart and circulatory physiology, 1992-06, Vol.262 (6), p.H1934-H1938

1992

Volltextzugriff (PDF)

Poststreptococcal reactive arthritis and silent carditis: a case report and review of the literature

Pediatrics (Evanston), 1994-05, Vol.93 (5), p.837

1994

Volltextzugriff (PDF)

1 – 25 von 238

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(210)
Mit Volltextzugriff
(188)

Publikationsform

Sprache

Englisch
(238)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales

Searching for the elusive familial hypercholesterolaemia gene mutations for index patients – using historical laboratory LDL-c results in primary care. A North Wales experience

Evolocumab & Inclisiran dual therapy for further LDL lowering in a very high cardiovascular risk Familial Hypercholesterolaemia patient with heterozygous gain of function PCSK9 mutation

Familial hypercholesterolaemia - geomapping of the baseline LDL levels and characterisation of LDL receptor mutations for patients diagnosed in the North Wales screening programme 2010–2015

Development of an e-learning program on Familial Hypercholesterolaemia (FH) for primary care

Relationship between measurements of non-HDL-cholesterol and LDL-cholesterol in Familial Hypercholesterolaemia

Optimising detection and management of Familial Hypercholesterolaemia (FH) – Revision of the FH Audit tool to monitor lipid levels

Web based tools to assess eligibility for genetic testing for Familial Hypercholesterolaemia (FH)

Dual therapy with inclisiran and evolocumab in a heterozygous FH patient while on maximum statin and ezetimibe dose to achieve LDL targets

Five year experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in wales: Should the criteria be refined to include age?

GENETIC VARIANTS OF UNCERTAIN SIGNIFICANCE (VUS) IN FAMILIAL HYPERCHOLESTEROLAEMIA (FH) IN WALES: YEAR 2 UPDATE

Implementation of a multidisciplinary approach to diagnosis and management of familial hypercholesterolaemia (FH) in Wales: The role of the FH specialist nurse

Genetic variants of uncertain significance (VUS) in familial hypercholesterolaemia (FH): Can family based association studies help determine pathogenicity?

Prevalence of high lipoprotein (A) amongst high cardiovascular risk population in North Wales, United Kingdom

Familial hypercholesterolaemia (FH) in Wales is genetically heterogeneous

Implementation of familial hypercholesterolaemia(FH) nurse led assessment clinics in South Wales

(9) Evaluation of genotype scoring criteria for familial hypercholesterolaemia (FH) in wales

Methyl isobutyl ketone (MIBK) induction of α2u-globulin nephropathy in male, but not female rats

Methyl isobutyl ketone (MIBK) induction of alpha 2u-globulin nephropathy in male, but not female rats

Neurodevelopmental outcome of infants with hypoplastic left heart syndrome

Dosimetry considerations in the enhanced sensitivity of male Wistar rats to chronic ethylene glycol-induced nephrotoxicity

Homozygous deletion in KVLQT1 associated with jervell and Lange-Nielsen syndrome

Mouse specific lung tumors from CYP2F2-mediated cytotoxic metabolism: An endpoint/toxic response where data from multiple chemicals converge to support a mode of action

Cardiac microdialysis in isolated rat hearts: interstitial purine metabolites during ischemia

Poststreptococcal reactive arthritis and silent carditis: a case report and review of the literature

Suchergebnisse filtern